Physician profile
Jason Ling
NPI 1154664597
$16,089.09
in general payments reported to CMS, 2019-2025
50 companies · $2,775 in 2025
The $2,775 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,066 · 2020: $543 · 2021: $1,480 · 2022: $2,360 · 2023: $2,765 · 2024: $3,101 · 2025: $2,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,640.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,192.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,736.13 | 2019-2025 | Tepezza, Evenity, Repatha |
| Novo Nordisk INC | $1,421.81 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $1,384.07 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $1,148.03 | 2020-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $995.63 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $868.76 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $625.29 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $553.71 | 2019-2022 | |
| Radius Health, INC. | $550.92 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $412.78 | 2019-2025 | |
| Abbvie INC. | $396.65 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $372.24 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Recordati_rare_diseases_inc. | $316.41 | 2023-2025 | Isturisa, Signifor Lar |
| Bayer Healthcare Pharmaceuticals INC. | $258.42 | 2021-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $240.35 | 2021-2024 | Minimed 780g |
| Ibsa Pharma INC. | $229.86 | 2019-2025 | Flector, Licart, Tirosint |
| Insulet Corporation | $225.93 | 2019-2025 | Omnipod |
| Horizon Therapeutics Plc | $195.81 | 2020-2023 | Tepezza |
| Mannkind Corporation | $173.51 | 2019-2025 | |
| Sequel Med Tech, LLC | $157.05 | 2025 | Twiist |
| Lifescan, INC. | $141.62 | 2019-2023 | |
| Tandem Diabetes Care, INC. | $139.36 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ucb, INC. | $133.32 | 2022 | |
| Alexion Pharmaceuticals, INC. | $125.86 | 2019-2025 | Strensiq |
| Becton, Dickinson and Company | $91.11 | 2022 | |
| Embecta Corp. | $88.92 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ascensia Diabetes Care US INC. | $86.79 | 2021-2025 | |
| Amarin Pharma, INC. | $70.61 | 2019-2022 | |
| Madrigal Pharmaceuticals | $69.84 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $69.24 | 2023-2025 | Qutenza |
| Neurocrine Biosciences, INC. | $59.02 | 2025 | |
| Kyowa Kirin, INC. | $55.45 | 2025 | |
| Janssen Pharmaceuticals, INC | $54.75 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $48.41 | 2019 | |
| Shield Therapeutics INC | $46.38 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $44.54 | 2025 | Yorvipath |
| Bigfoot Biomedical INC | $42.84 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $36.97 | 2022-2023 | Imcivree |
| Amphastar Pharmaceuticals, INC. | $36.22 | 2024-2025 | |
| Cequr Corporation | $24.21 | 2023 | Cequr Simplicity |
| Verity Pharmaceuticals INC. | $24.17 | 2025 | Tlando |
| Astellas Pharma US INC | $23.97 | 2024 | Veozah |
| Valeritas, INC. | $23.59 | 2019 | |
| Pfizer INC. | $17.57 | 2023 | |
| Beta Bionics, INC. | $17.32 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $17.30 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.57 | 2022 | |
| Currax Pharmaceuticals LLC | $13.94 | 2022 | |
| Amryt Pharma Holdings LTD | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.